24 November - 27 November Milan
6-P | Clinical performance of -2 pro-prostate-specific antigen and Prostate Health Index for prediction of prostate cancer in a cohort of Spanish men | Angeles Sanchis-Bonet | Received |
7-P | Prostate cancer risk in relation to Insulin-like Growth Factor-1, IGF-Binding Protein-3 and Body Mass Index | Angeles Sanchis-Bonet | Received |
8-P | What the urologist needs to know | Adalgisa Guerra | Received |
16-P | Image guided radiotherapy with fiducial markers and intensity modulated radiotherapy in prostate cancer. Long terms outcomes | Carmen Salas | Received |
17-P | Implementation and effects of three Dutch decision aids for prostate cancer: Results from the JIPPA study | Julia van Tol-Geerdink | Received |
22-P | Laparoscopic salvage lymph node dissection in biochemical recurrence after radical prostatectomy and salvage radiotherapy. Feasibility, security, and results | Teresa Renedo Villar | Received |
24-P | Implantations of fiducials gold markers in the prostate for Image Guided Radiotherapy. Experience of a university hospital | Carmen Salas | Received |
61-P | Circulating tumor cells as liquid biopsies of prostate cancer bone metastases | Karin Welén | Received |
67-P | Stereotactic body radiotherapy for nodal oligorecurrent prostate cancer: A multi-institutional analysis | Piet Ost | Received |
77-P | Real-world outcomes of enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: A retrospective, multicenter study in Korea | Minyong Kang | Received |
78-P | Is there still a place for docetaxel rechallenge in metastatic castrate resistant prostate cancer? | Rodica Anghel | Received |
86-P | Impact of new therapies in the treatment of metastatic Castration Resistant Prostate Cancer (CPRCm): Retrospective analysis in a single institution in 2005-2015 | Olatz Etxaniz Ulazia | Received |
87-P | Docetaxel chemotherapy in hormone-sensitive prostate cancer: A single-institution experience | Mario Uccello | Received |
88-P | Laparoscopic salvage lymphadenectomy in patients treated with biochemical recurrence after radical prostatectomy after initially extended LND: Safety and objective response rate | Sergey Reva | Received |
89-P | Salvage high-dose-rate brachytherapy for macroscopic local recurrence after radical prostatectomy | David Buchser | Received |
98-P | Availability of prostate cancer rehabilitation resources and practice patterns: Results of a national survey | Piet Ost | Received |
100-P | Urachal carcinoma: A retrospective analysis of a reference cancer center | Ins Guerreiro | Received |
121-P | Baseline clinicopathological features as predictive markers of efficacy of Neoadjuvant Chemotherapy (NAC) in Muscle-Invasive Bladder Cancer (MIBC) | Albert Font Pous | Received |
124-P | Preoperative neutrophil to lymphocyte ratio as a predictor marker of adverse outcomes in patients undergoing radical cystectomy due to bladder cancer | Ariadna Fabià Mayans | Received |
135-P | The prognostic role of tissue TIMP-2 expression in patients with renal cell carcinoma | Pastora Beardo-Villar | Received |
137-P | Long-term response to mTOR inhibitors (everolimus) in mRCC patients: Single institution experience | Joanna Huszno | Received |
139-P | Comparison of sunitinib versus temsirolimus in patients with poor risk metastatic renal cell carcinoma | David Sarid | Received |
140-P | Outcome of octogenarian versus young patients with metastatic renal cell carcinoma, treated with sunitinib | David Sarid | Received |
146-P | Preoperative lipiodol marking improved safety and success rate on CT-guided cryoablation for small renal masses | Fumiya Hongo | Received |
149-P | Impact of precise quantitative assessment of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy | Ryuichi Mizuno | Received |
155-P | A double rare testicular cancer: Burned out tumor with vena cava thrombus presentation | Pedro Oliveira | Received |
24 November - 27 November Milan
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|